THE USE OF SACUBITRIL/VALSARTAN IN HEART FAILURE: A LITERATURE REVIEW

Abstract

This article aimed to analyze the use of sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), which has become one of the main therapies for managing heart failure (HF), especially in patients with reduced ejection fraction (HFrEF). Due to its synergistic action, it promotes vasodilation, natriuresis, and favorable cardiac remodeling. Clinical studies, multicenter trials, and cohort analyses indicate that ARNI reduces hospitalizations, improves cardiac function, and preserves renal function, with consistent effects across different populations and geographic contexts. Despite these benefits, adverse events such as hypotension and nasal pruritus have been observed in specific subgroups; however, overall tolerability is generally acceptable, even in patients with advanced HF. In heart failure with preserved ejection fraction (HFpEF), results are heterogeneous, suggesting the need for individualized medical management. This literature review concluded that sacubitril/valsartan represents an effective and safe therapy for HFrEF, with potential benefits in HFpEF when properly monitored.